Gravity Analytica

Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

SUPN 10.21.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-04

Name of Upcoming Event:Conference Call

Full Press Release SEC Filings Our SUPN Tweets

About Gravity Analytica

Recent Filings

PDF Version

ROCKVILLE, Md.,Oct. 21, 2024(GLOBE NEWSWIRE) --Supernus Pharmaceuticals, Inc.(Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the third quarter of 2024 after the market closes onMonday, November 4, 2024.

Jack Khattar, President and CEO, andTim Dec, Senior Vice President and CFO, will host a conference call to present the third quarter 2024 financial and business results onMonday, November 4, 2024at4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.

A live webcast will be accessible in theEvents & Presentationssection of the Company’s Investor Relations website atwww.supernus.com/Investors.

Participants may also pre-register any time before the callhere. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.

Following the live call, a replay will be available on the Company's Investor Relations website atwww.supernus.com/Investors. The webcast will be available on the Company’s website for 60 days following the live call.

AboutSupernus Pharmaceuticals, Inc.

Supernus Pharmaceuticalsis a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, and dyskinesia in PD patients receiving levodopa-based therapy. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.

For more information, please visitwww.supernus.com.

CONTACTS:

Jack A. Khattar, President and CEOTimothy C. Dec, Senior Vice President and CFOSupernus Pharmaceuticals, Inc.Tel: (301) 838-2591

INVESTOR CONTACT:Peter VozzoICR WestwickeOffice: (443) 213-0505Mobile: (443) 377-4767Email:peter.vozzo@westwicke.com

Source: Supernus Pharmaceuticals, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com